featured
Single-Agent Capecitabine Increases Progression-Free Survival in mCRC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Single-Agent Capecitabine as Maintenance Therapy After Induction of XELOX (or FOLFOX) in First-Line Treatment of Metastatic Colorectal Cancer: Randomized Clinical Trial of Efficacy and Safety
Ann. Oncol 2016 Mar 02;[EPub Ahead of Print], HY Luo, YH Li, W Wang, ZQ Wang, X Yuan, D Ma, FH Wang, DS Zhang, DR Lin, YC Lin, J Jia, XH Hu, JW Peng, RH XuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.